Touchscreen-compatible, real-time electrochemical sensing of SARS-CoV-2

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 4U01AA029316-02

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2023
  • Known Financial Commitments (USD)

    $455,938
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    PROFESSOR Suzie Pun
  • Research Location

    United States of America
  • Lead Research Institution

    UNIVERSITY OF WASHINGTON
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

PROJECT SUMMARY The SARS-CoV-2 coronavirus, the cause of the COVID-19 global pandemic, is efficiently spread and has reached over 27 million confirmed cases as of September 8, 2020. There is therefore an urgent need for new technologies that can provide early detection of virus, reducing the transmission and infection rate. The goal of this proposal is to develop an integrated biosensor- touchscreen that sensitivity reports surface contact with SARS-CoV-2. In our preliminary work, we have identified several aptamers that bind specifically to the envelope-anchored trimeric spike (S) protein of SARS-CoV-2, but not of SARS-CoV or MERS. In comparison to antibodies, aptamers are synthetic molecules that more thermally stable and lower cost while providing similar specificity and affinity of target binding. In this application, we propose to integrate aptamer-based biosensing of SARS-CoV-2 into a touchscreen device. Our main objectives are to 1) engineer conformation switching aptamers for electrochemical sensing of SARS-CoV-2 binding, 2) develop nanogap capacitive sensors as a uniquely complementary approach to capacitive touchscreen technology and 3) build and test an integrated biosensor and touchscreen array that can detect SARS-CoV-2 from patient samples. Successful completion of these aims will result in a novel automatic sensing platform for SARS-CoV-2. This technology could transform personal device touchscreens as well as to multi-user touchscreen devices in hospitals, airports, libraries, restaurants, for early detection, curbing transmission rates from secondary exposure. Importantly, the developed technology could be adapted for other electronic sensing platforms, and easily applied for future pathogen detection.